0.50Open0.50Pre Close0 Volume263 Open Interest7.50Strike Price0.00Turnover183.13%IV3.31%PremiumJan 17, 2025Expiry Date0.26Intrinsic Value100Multiplier1DDays to Expiry0.24Extrinsic Value100Contract SizeAmericanOptions Type-0.6015Delta0.4754Gamma15.24Leverage Ratio-0.1436Theta-0.0002Rho-9.17Eff Leverage0.0017Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet